Alicia McElhaney

Recent Articles By The Author

Immunomedics Soars on Injunction Against Seattle Genetics Deal

Immunomedics Soars on Injunction Against Seattle Genetics Deal

The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.

Valeant Launches Loan Offering Days After Paying Down $1.1 Billion in Debt

Valeant Launches Loan Offering Days After Paying Down $1.1 Billion in Debt

This offering puts Valeant's debt at roughly $31 billion.

Politicians Question EpiPen Competitor's High Pricetag

Politicians Question EpiPen Competitor's High Pricetag

Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.

Here's Why Weight Watchers' New CEO Should Be a Woman

Here's Why Weight Watchers' New CEO Should Be a Woman

Could Oprah Winfrey herself take the helm at the diet company?

Valeant Plummets for Second Day

Valeant Plummets for Second Day

The company's shares continued to fall after news that the drug company will take on more debt.

Valeant Shares Dive on Reports of New Debt

Valeant Shares Dive on Reports of New Debt

The Laval, Quebec-based biotech announced that it would pay down $1.1 billion in debt Monday.

Mylan's Governance May Be the Root of Its Problems

Mylan's Governance May Be the Root of Its Problems

The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.

With Big Hopes for Cancer Drug, Kite Raising $350M

With Big Hopes for Cancer Drug, Kite Raising $350M

The pharma is gearing up to commericialize its lead drug, a treatment for lymphoma.

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Forty states have now sued the companies.

Valeant Gets Rocked as Investors Weigh Ability to Drive Organic Growth

Valeant Gets Rocked as Investors Weigh Ability to Drive Organic Growth

The company also has a huge pile of debt hanging over its head.